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Background: Standard stratiﬁcation criteria in studies evaluating 
patients (pts) with locally advanced NSCLC generally include gender, 
stage, & weight loss, occasionally age and histology. However, con-
temporary analyses of more recent trials in LA-NSCLC to determine if 
these factors are still prognostic have not been conducted. 
Materials and Methods: We evaluated the baseline demographics of 
two separate phase III trials: (1) RTOG 9410, a randomized phase III 
trial in good prognosis LA-NSCLC comparing sequential cisplatin-
based chemotherapy followed by RT (63 Gy) to concurrent chemother-
apy & either once daily RT (63Gy) or twice daily (BID) RT (69.6 Gy) 
(platinum dose in each arm was equivalent) & (2) RTOG 9801, a phase 
III trial evaluating induction chemotherapy with paclitaxel & carbopla-
tin followed by concurrent BID RT, weekly paclitaxel & carboplatin ± 
amifostine. We assessed the distribution of prognostic variables in each 
study, & then analyzed hazard ratios, conﬁdence intervals, & p values 
for each potential prognostic factor, including age, stage, N status, 
histology, gender, KPS, tumor location, and hemoglobin. We then as-
sembled risk models with multiple prognostic factors in combination.
Results: 824 evaluable pts were accrued to these 2 efforts: 585 to 
RTOG 9410; 239 to RTOG 9801. 82% were under 70; 56% had stage 
IIIB NSCLC, 37% had squamous histology. 64% were male. 19% had 
N0-1 disease, 53% N2, 27% N3. KPS was 90-100 in 75%. 22% had 
primary tumor location in the lower lobe or multiple lobes. Baseline 
median hemoglobin was 13.4; 17% had baseline hemoglobin under 12. 
At this point 110 patients (13% of total enrollment) remain alive; 10% 
of those enrolled on 9410 with a median follow-up of 6 yrs, & 22% of 
those on 9801 with a median follow-up of 3 yrs. In univariate analysis 
by Cox modeling, KPS (90-100 versus 70-80; p=0.0002) & N status 
(N0 vs N1 vs N2 vs N3, p=0.0048) were highly prognostic; gender 
(female vs male; p=0.0481) & lobar location (upper lobe versus lower 
or multilobe; p=0.0206) were borderline prognostic. Age (<70 vs. >70, 
p=0.28), stage (II/IIIA vs. IIIB, p=0.16), histology (non-squamous vs. 
squamous, p=0.085) & hemoglobin (<12 vs. < 12, p=0.62) were not 
prognostic. 
Age, stage, gender, N status (0, 1 vs 2, 3), KPS, histology, tumor loca-
tion & Hgb were dichotomized into 2 levels, one level corresponding 
with a worse prognosis, the other a better prognosis; pts were then 
grouped into three cohorts of combined poor prognosis factors 0, 1 vs 
2, 3 vs >3. The distribution and hazard ratios follow:
# of Prognostic 
Factors
9410 
(n-578)
9801 
(n=232)
Total 
(n=810)
HR 95% CI p value
MS 
(mos)
0, 1 41 (7%) 22 (9%) 63 (8%) 1.00 - - - - 22.7
2, 3 308 (53%)
120 
(52%)
428 
(53%) 1.31 (0.99, 1.79) 0.0585 17.3
>3 229 (40%) 90 (39%)
319 
(39%) 1.74 (1.28, 2.35) 0.0003 13.5
 
Conclusions: Independently, KPS, tumor location, N status, & gender 
have proven prognostic in platinum-based RTOG trials. However, 
prognostic modeling in LA-NSCLC, in the setting of non-operative 
combined modality therapy, is best performed by assessing multiple 
risk factors simultaneously rather than 1 variable at a time. Our evi-
dence-based joint analysis improves our prognostic ability & consti-
tutes a more clear-headed approach toward therapeutic stratiﬁcation in 
the presence of multiple prognostic variables. Observations from this 
analysis will help determine future stratiﬁcations in RTOG trials. 
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Background: Our previous IPD meta-analyses of CT in locally ad-
vanced NSCLC suggested that adding sequential CT to radiotherapy 
improved survival (BMJ 1995;311:899) and that adding concomitant 
CT to radiotherapy could also improve survival (inconsistent results in 
sensitivity analyses) (Ann Oncol 2006;17:473). The NSCLC Collabora-
tive Group reports here the update of these meta-analyses.
Methods: Systematic searches for RCTs were followed by central 
collection, checking and re-analysis of updated IPD. Results from indi-
vidual trials were combined using the stratiﬁed (by trial) log-rank test 
to calculate pooled hazard ratios (HRs). Previously included old trials 
using deleterious long-term alkylating agents were excluded from the 
updated sequential CT analysis.
Results: 31 RCTs were eligible for the meta-analysis of sequential CT. 
IPD was received from 21 RCTs (3473 patients) and only survival HR 
from one RCT (366 patients, IPD soon available). The survival analysis 
was based on these 22 trials and 3839 patients (78% of all known 
randomised patients). This adds 5 trials (1471 patients) to the 1995 
analysis. Median follow-up was 6.9 years. Sixteen trials used induction 
CT±alternated or consolidation CT, 7 used consolidation±concomitant 
CT or alternated CT. One trial had one part on induction and another 
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on consolidation CT. Thirteen trials used cisplatin+vinca alkaloid/eto-
poside, 1 used carboplatin+taxane, 2 used other platinum regimens, 
3 used vinca-alkaloid and 3 used other non platinum regimens. There 
was a signiﬁcant beneﬁt of sequential CT on survival (HR=0.88, 95% 
CI=[0.82-0.94], p=0.0001), with an absolute beneﬁt of 2.6% (from 
8.7% to 11.3%) at 3 years. There was no clear evidence of a difference 
in effect by type or timing of CT. Nor was there clear evidence that any 
patient subgroup deﬁned by age, sex, performance status, histology or 
stage beneﬁted more or less from sequential CT.
21 RCTs were eligible for the meta-analysis of concomitant CT. 
IPD was received from 15 RCTs (2733 patients) and only survival 
HR from one RCT (177 patients, IPD soon available). The survival 
analysis was based on these 16 trials and 2910 patients (87% of all 
known randomised patients). This adds 7 trials (1145 patients) to the 
previous analysis. The progression-free survival (PFS) analysis was 
based on 12 trials and 2034 patients. Median follow-up was 5.3 years. 
Nine trials used cisplatin or carboplatin alone, 3 used cisplatin or 
carboplatin+etoposide, 1 used carboplatin+taxane and 3 used taxane 
alone. In 4 trials, induction CT was added in both arms. There was 
a signiﬁcant beneﬁt of concomitant CT on survival (HR=0.88, 95% 
CI=[0.81-0.95], p=0.0008), with an absolute beneﬁt of 3.2% (from 
13.4% to 16.6%) at 3 years. Exclusion of trials with incomplete data 
did not change the results. There was a signiﬁcant beneﬁt of concomi-
tant CT on PFS (HR=0.81, 95% CI=[0.74-0.89], p<0.0001). There was 
no clear evidence that any patient subgroup beneﬁted more or less from 
concomitant CT.
Conclusions: These results demonstrate now a beneﬁt of sequential 
and concomitant CT in locally advanced NSCLC treated by RT. They 
provide robust estimates for future policies and research.
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Background: The previous IPD meta-analyses of CT in locally ad-
vanced NSCLC indicated that adding sequential CT to radiotherapy im-
proved survival (BMJ 1995;311:899) and that adding concomitant CT 
to radiotherapy could also improve survival (Ann Oncol 2006;17:473). 
The NSCLC Collaborative Group performed a meta-analysis of RCTs 
that compared concomitant RT-CT versus sequential RT-CT.
Methods: Systematic searches for RCTs were followed by the central 
collection, checking and re-analysis of updated IPD. Results from 
individual trials were combined using the stratiﬁed (by trial) log-rank 
test to calculate pooled hazard ratios (HRs). The primary outcome was 
overall survival, secondary outcomes were progression-free survival 
(PFS), cumulative incidences of loco-regional progression and of 
distant progression and acute toxicity (haematological, pulmonary, 
oesophageal).
Results: Seven trials which randomized 1,301 patients were eligible for 
the meta-analysis. IPD was received from 1,114 patients from 5 RCTs 
(86% of all known randomised patients). The HR for overall survival 
was also provided for one RCT (85 patients, IPD soon available). The 
main survival analysis was based on these 6 trials and 1,199 patients 
(92% of all randomized patients). Median follow-up was 5 years. The 
PFS analyses were based on the 5 trials with IPD. Two trials used same 
drugs and doses for concomitant and sequential CT. For sequential CT, 
all trials used at least cisplatin, induction CT was used in 5 trials and 
consolidation CT in one. For concomitant CT, cisplatin was used in 5 
trials with daily administration in 2 trials, and carboplatin was used in 
one trial. One trial used consolidation CT after concomitant CT. RT 
dose was lower than 60 Gy in 2 trials and RT was different between 
the two arms in one trial (same total dose but split course used in the 
concomitant arm).
Concomitant RT-CT increased acute oesophageal toxicity (grade 
3-4) from 3% to 18% with a relative risk of 5.7 (95% CI=[3.5-9.5], 
p<0.0001). There was no signiﬁcant difference between concomitant 
and sequential RT-CT for pulmonary acute toxicity. Haematological 
toxicity rates were highly variable among trials and the data were not 
pooled.
There was a signiﬁcant beneﬁt of concomitant RT-CT as compared 
to sequential RT-CT on survival (HR=0.83, 95% CI=[0.73-0.94], 
p=0.0026), with an absolute beneﬁt of 6.6% (from 18.2% with sequen-
tial RT-CT to 24.8% with concomitant RT-CT) at 3 years. For progres-
sion-free survival, the HR was 0.89 (95% CI=[0.78-1.00], p=0.0585). 
Concomitant CT decreased loco-regional progression (HR=0.76, 95% 
CI=[0.62-0.94], p=0.011), but its effect was not different from that of 
sequential CT on distant progression (HR=1.04, 95% CI=[0.86-1.25], 
p=0.669). There was no clear evidence of a difference in effect by type 
of CT. Nor was there clear evidence that any patient subgroup deﬁned 
by age, sex, performance status, histology or stage beneﬁted more or 
less from concomitant CT. 
Conclusions: Concomitant RT-CT, as compared to sequential RT-
CT, improved survival of patients with locally advanced NSCLC, 
mainly due to the decrease of loco-regional progression, at the cost of 
increased acute oesophageal toxicity.
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